References
Hoch W, McConville J, Helms S et al (2001) Auto antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368
Evoli A, Tonali PA, Padua L et al (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126:2304–2311
Cragg MS, Walshe CA,Ivanov AO, Gleennie MJ (2005) The biology of CD20 and its potential as the target for mAb therapy. Curr Dir Autoimmun 8:140–174
Hain B, Jordan K, Deschauer M (2006) Successful treatment of MuSK antibodypositive myasthenia gravis with rituximab. Muscle Nerve 33(4):575–580
Wylam ME, Anderson PM, Kuntz NL, Rodriguez V (2003) Successful treatment of refractory myasthenia gravis using Rituximab: a pediatric case report. J Pediatr 143(5):674
Raja F, Russo D, Fuga G, Perella G, Baccarani M (2000) Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55:1062–1063
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thakre, M., Inshasi, J. & Marashi, M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 254, 968–969 (2007). https://doi.org/10.1007/s00415-006-0442-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-006-0442-2